RGD-TRAIL抗肿瘤作用的细胞筛选研究

发布时间：2018-01-19 00:31

本文关键词： RGD-TRAIL 抗肿瘤细胞筛选　出处：《中国新药杂志》2015年09期 　论文类型：期刊论文

【摘要】：目的:通过体外细胞实验,来确定对RGD-TRAIL的敏感肿瘤细胞株,为体内试验提供参考。方法:利用靶向抗肿瘤蛋白RGD-TRAIL处理30株人肿瘤细胞系72 h后,通过CTG方法测定药物在各个肿瘤细胞系中的细胞增殖50%抑制浓度(IC50),来确定对RGD-TRAIL的敏感肿瘤细胞株。结果:在所有测试的肿瘤细胞系中,对RGD-TRAIL最为敏感的是COLO 205,A-673和NCI-H358,它们的IC50皆小于0.05μg·m L-1;其次MDA-MB-231和Calu-3对RGD-TRAIL也较敏感,IC50值分别为0.3和1.9μg·m L-1;其余细胞系对RGD-TRAIL的IC50值均大于40μg·m L-1。结论:对RGD-TRAIL敏感的肿瘤细胞株为COLO 205(结肠癌)、A-673(骨癌)和NCI-H358(非小细胞肺癌)。
[Abstract]:Objective: to determine the sensitive tumor cell line to RGD-TRAIL by cell experiment in vitro. Methods: 30 human tumor cell lines were treated with targeted antitumor protein RGD-TRAIL for 72 h. CTG assay was used to determine the inhibitory concentration of the drug on the proliferation of 50% cells in various tumor cell lines (IC50). Results: of all the tumor cell lines tested, COLO 205 was the most sensitive to RGD-TRAIL. The IC50 of A-673 and NCI-H358 were less than 0. 05 渭 g 路ml ~ (-1); Secondly, the IC50 values of MDA-MB-231 and Calu-3 to RGD-TRAIL were 0.3 and 1.9 渭 g 路ml ~ (-1), respectively. The IC50 value of other cell lines to RGD-TRAIL was more than 40 渭 g 路m -1. Conclusion: the tumor cell line sensitive to RGD-TRAIL is COLO 205 (colon cancer). . A-673 (bone cancer) and NCI-H358 (non-small cell lung cancer).
【作者单位】：常州千红生化制药股份有限公司;
【基金】：国家“重大新药创制”科技重大专项(2009ZX09103-675,2012ZX09401012) 常州市科技支撑计划(社会发展)(CE20115044)
【分类号】：R96
【正文快照】： RGD肽是一类含有精氨酸-甘氨酸-天冬氨酸(Arg-Gly-Asp)的短肽,作为整合素和其配体相互作用的识别位点,介导细胞与细胞外基质及细胞之间的相互作用。RGD肽可介导肿瘤的靶向治疗,抗肿瘤药物及其递送系统经过RGD肽修饰,可以增加药物的肿瘤主动靶向特性,达到更有效、精确和安全的

【参考文献】